CD34 and carcinoma: By co-staining with anti-CD45, CD34 and TE7 antibodies [31], we were able to label the different subpopulations as leukocytes (CD45+), endothelial cells (CD34+), fibroblasts (TE7+) and lineage (LIN)-negative cells (i.e. carcinoma cells).